Are covid-19 vaccine-induced adverse cardiovascular events rare?

When compared with Flu vaccines, Covid vaccines are much more dangerous

COVID-19 vaccine-induced adverse cardiovascular events (ACEs) have been judged as “rare” (and many times as mild and temporary) by the major promoters of these vaccines (caveat: these injections prevent neither infection nor viral transmission, so they are not vaccines in the classical sense). To ascertain the frequency of COVID-19 vaccine-induced ACEs, we have examined the Vaccine Adverse Events Reporting System (VAERS) database for reports of ACEs. Since some ACEs can have latency/incubation periods of a decade or more, we have also addressed the issue of Early Warning Indicators that could identify COVID-19 vaccine-induced ACEs on or over the horizon. Finally, we have compared ACEs reported following COVID-19 vaccines with those reported following influenza vaccines for similar numbers of vaccine doses delivered. In Appendix 1, we have also addressed the relevance of human clinical trials to the issues addressed in this OpEd.

While imperfect (as are most publicly-available vaccine adverse events reporting systems), VAERS is a reasonable system for identifying safety signals related to vaccines. One major VAERS deficiency is that only a small fraction of vaccine-related adverse events is reported to VAERS. A study by Harvard Pilgrim Health Care, using electronic tracking, showed that “fewer than 1% of vaccine adverse events are reported”. This is an average value over all adverse events; it may be worse for some ACEs.

The Harvard Pilgrim Health Care study tracked reporting habits to VAERS for thirty days. Therefore, the 1% number should be termed a thirty-day reporting fraction. For adverse events that tend to occur rapidly, like headache, fever, chills, rashes, anaphylactic shock, blood clots, etc., a thirty-day study may offer a reasonable window. Some ACEs, however, may take a decade or more to emerge, and a thirty-day window would be grossly inadequate for accurate reporting. The numbers shown in the present analysis should be viewed as a “floor” of what the real-world numbers are. To get a more complete picture of the total ACEs of the COVID-19 vaccines, these numbers should be supplemented by ACE Early Warning Indicators whose abnormal values could emerge shortly after the injection, and allow some prediction of what lies on or over the horizon.

METHODOLOGY

The VAERS database was initially accessed on 20 December 2022. The vaccines were limited to COVID-19 vaccines from all manufacturers, and the VAERS reports were for the USA. All adverse event types (termed Symptoms in VAERS) were retrieved. There were ~17,000 adverse event types retrieved, including ~5,000 with zero entries (the latter were not analyzed, although when scaling from VAERS entries to real-world numbers, they could possibly amount to tens of events for each symptom). A comprehensive query (consisting of myriad synonyms of ACEs) was used to search the VAERS database, and retrieve ACE-related adverse events.

On 10 February 2023, the VAERS database was accessed to get similar information for the influenza vaccines from all manufacturers, and the VAERS reports were for the USA. The time period for the latter was selected to cover similar numbers of doses for the flu vaccines and the COVID-19 vaccines.

On 14 February 2023, the VAERS database was accessed to obtain parametric proximity data for assessing the fraction of ACEs that were reported seven and fourteen days past injection.

RESULTS

Before presenting the numbers, we need to define what is an ACE event reported in VAERS. Is it 1) a biomarker associated with the eventual emergence of ACE, 2) a group of biomarkers reflecting pre-clinical ACE, 3) a newly-diagnosed ACE, 4) an ACE that has been exacerbated, or 5) an ACE death? While all five are valid candidates, the present study concentrates on items 3) and 4), with the one exception that Troponins were included (since they were listed as a possible event).

This restriction to items 3) and 4) substantially under-reports the COVID-19 vaccine adverse events that may eventually result in ACEs, because it excludes abnormalities in ACE risk biomarkers (with the exception of Troponins). These abnormalities in the appropriate ACE risk biomarkers would provide an Early Warning Indicator for potential ACEs to emerge in the near or far future. A few potential Early Warning Indicators for ACEs are shown in the following: myocardial injury (Cardiac troponin I (cTnI) and T (cTnT), High-sensitivity cardiac troponin (hs-cTn), Heart-type fatty acid binding protein (H-FABP)); inflammation (High-sensitivity C-reactive protein (hsCRP), Growth-differentiation factor-15 (GDF-15), Fibrinogen, Uric acid (UA)); plaque instability/rupture (Pregnancy-associated plasma protein-A (PAPP-A), Myeloperoxidase (MPO), Matrix metalloproteinases (MMPs)); platelet activation (Lipoprotein-associated phospholipase A2 (Lp-PLA2), Secretory phospholipase A2 (sPLA2), Soluble CD40 ligand (sCD40L)); neurohormonal activation (Copeptin, Mid-regional-pro-adrenomedullin (MR-proADM)); myocardial dysfunction or stress (Natriuretic peptides, ST2, Endothelin-1 (ET-1), Galectin-3 (Gal3), Neuregulin-1 (NRG-1)); microRNAs (miRNAs). A broader group of ACE biomarkers, which includes most of the biomarkers listed above, can be found in Figure 1 of the following link, and a broader group can be found in Table 1 of the following link.

Most of the ACE risk biomarkers listed above did not appear in the VAERS output for Symptoms, even for the events that have zero entries. Assessment of abnormalities in these risk biomarkers would provide a more accurate picture of what can be expected in the mid and long-term from the injections given already.

The results for items 3) and 4), and Troponins, follow. There were ~1020 different ACEs reported in VAERS for the COVID-19 vaccines, with ~156000 total number of events. Converting these VAERS entries to real-world numbers of COVID-19 vaccine-induced ACEs requires three major assumptions, and some minor ones. The major assumptions are 1) the ACEs reported in VAERS following the administration of COVID-19 vaccines are in fact caused in part or in whole by the COVID-19 vaccines, 2) the under-reporting factor (URF) to be used for ACE scale-up to real-world numbers can be approximated for very conservative estimation purposes by the Harvard Pilgrim Healthcare thirty-day URFs, and 3) the fraction of the VAERS ACE entries to which the URF should be applied can be approximated by autopsy results for fraction of post-COVID-19 vaccine deaths that can be attributed to the COVID-19 vaccine.

Assumption 1)

Assumption 1) is based on four sources of evidence: i) the biological mechanisms responsible for cardiovascular damage; ii) the autopsy results confirming the operability of the biological mechanisms; iii) a comparison with similar influenza vaccination data to estimate the cardiovascular damage expected (based on extrapolations of pre-pandemic adverse cardiovascular events); and iv) a parametric study showing the fraction of symptoms that occurred within seven and fourteen days of onset from the injections.

i). Biological Mechanisms

The COVID-19 mRNA vaccines are injected in the deltoid muscle, and a fraction enters the bloodstream directly or indirectly (link 1; link2). The mRNA that enters the bloodstream is able to survive because of protection by the LNP encapsulation. As the Pfizer pharmacovigilance studies showed, the LNP package concentrates in a number of organs.

The damage to the blood vessels in the circulatory system, and then to the tissues and organs, has been described most eloquently in a video by Dr. Sucharit Bhakdi, a world-renowned microbiologist: “the vaccines cause cells deep inside our body to express the viral spike protein, which they were never meant to do by nature. Any cell which expresses this foreign antigen on its surface will come under attack by the immune system, which will involve both IgG antibodies and cytotoxic T-lymphocytes. This may occur in any organ, but the damage will be most severe in vital organs. We are seeing now that the heart is affected in many young people, leading to myocarditis or even sudden cardiac arrest and death.”.

Thus, while all tissues and organs in the body will be potential targets of this induced autoimmune process, those of the circulatory system will be prime targets because of their proximity to the circulating LNP-enclosed mRNA. The spike proteins expressed on the surface of the endothelial cells (those that line the interior of the blood vessels and are in closest proximity to the innate immune system components flowing by in the bloodstream) are able to interact with the platelets flowing by and initiate the clotting process. So, the net effect is coagulation and clotting of the blood, destruction of the endothelium, and subsequent destruction of the tissues and organs as the LNP package transitions from the bloodstream through the ruptured endothelium into the surrounding tissues and organs.

Given this mode of action, the question we should be asking is not why we are experiencing such large numbers of ACES, but rather why wouldn’t we expect a massive number of ACEs resulting from these vaccinations? In some sense, why doesn’t almost every mRNA vaccine recipient experience one or more ACEs?

The answer may lie in the existence of so-called “hot lots”. Some analysts have correlated VAERS vaccine lot numbers with serious adverse events, and have found some of the vaccine lots are responsible for far more serious adverse events than other lots (link 1; link 2). Explanations for this are manifold, but shoddy manufacturing processes are one credible explanation. Many/most of the vaccines produced are not fully functional, and their potential for damage is muted. If this turns out to be true after further validation, it means the toxicity of the mRNA vaccines per functional dose are higher than have been calculated.

The ACEs represented in the peer-reviewed literature have focused on myocarditis (e.g., link 1; link 2; link 3; link 4; link 5). Because of the censorship that exists in the biomedical peer-reviewed literature today, many other ACEs have not been addressed. However, as Appendix 2 shows, the different types of ACEs are monumental, as one would expect from the operational mechanisms of the injectant, and some ACEs are large compared to myocarditis. The alternative biomedical literature is a much more credible source of real-world information on the causes and extent of ACEs.

ii). Autopsy Results

Autopsies have been the most credible source of information about the extent of the COVID-19 vaccine-induced damage, although they have been discouraged by governments around the world. Some that have been made available show the extent of the damage in detail, and confirm the theory of damage expressed by Dr. Bhakdi and many others. While different organs may receive the bulk of the damage in different individuals, most autopsies show the heart to be a major target. Typically, the autopsies show the spike protein infiltration into an organ (or tissue), the rupture of the endothelium, and the infiltration of the lymphocytes (which attack the cells that express the spike protein on the surface and thereby damage the organ (or tissue)). This infiltration of spike protein appears to be a classic convection-diffusion process, with convection mainly through the bloodstream and diffusion through the tissues/organs. As long as the body continues to function like a spike protein factory, which appears to be one consequence of the injection, the infiltration of spike protein and associated damage will continue. With the addition of periodic boosters, the spike protein “factory” is replenished, and the damage will continue to spread. It is difficult for me to see how anyone who has been injected with a functional mRNA vaccine can avoid this damage, and the associated adverse effects on lifespan.

iii). Comparison with Similar Influenza Vaccination Data

The VAERS entries for ACEs can be viewed as consisting of two parts: the numbers expected for any ACE based on extrapolation of historical pre-pandemic trends, and the numbers for the ACE due to the COVID-19 vaccines. Since the numbers expected would be about the same for influenza and COVID-19, these background numbers can be bounded based on the influenza data. We did a simple comparison of some of the highest frequency ACEs reported here with their counterparts for the influenza vaccines reported in VAERS. We selected influenza, since it is a respiratory viral disease and has a number of features in common with COVID-19.

There have been about 670 million doses of COVID-19 vaccines administered in the USA since late December 2020, and about 717 million doses of influenza vaccines administered in the USA since the beginning of 2019. Thus, the number of doses is relatively similar for the influenza vaccines and the COVID-19 vaccines over the time periods selected. Table 1 compares VAERS entries for selected ACEs (those with high entry numbers for COVID-19 vaccines) between influenza vaccines and COVID-19 vaccines.

Thus, for similar dose numbers, and an even longer average tracking times for the flu vaccines, the VAERS ACEs entries for the flu vaccines are almost two orders of magnitude less than for the COVID-19 vaccines. While the number of ACEs induced by the vaccines could be vastly different for the two cases, one would expect the background levels of ACEs (the numbers of ACEs expected based on extrapolation of historical trends) to be roughly similar. If anything, they would be larger for the flu vaccines because of the increased time period over which they were administered relative to the COVID-19 vaccine administration period.

The small number of ACEs (<2% of COVID-19 numbers) reported for the flu vaccines would suggest 1) most of the COVID-19 ACE entries were vaccine-induced, and 2) the ACE onsets following injection were accelerated sufficiently by the COVID-19 injections that the ACEs could be linked to the shots and would motivate reporting to VAERS by the healthcare provider! Conversely, in the case of the flu vaccines, almost all ACEs that occurred post-vaccine may have been sufficiently far removed in time from the injection that the healthcare provider was not motivated to report them to VAERS.

Additionally, I have seen many videos of testimonies by healthcare providers that they were heavily discouraged from reporting post-COVID-19 vaccine adverse events to VAERS, while I have never seen or read of similar discouragement for flu vaccine reporting. This deliberate suppression of reporting post-COVID-19 vaccine adverse events to VAERS lends further argument for increasing the URFs of COVID-19 vaccine adverse events.

https://www.trialsitenews.com/a/are-covid-19-vaccine-induced-adverse-cardiovascular-events-rare-01b2657e

***************************************************

Also see my other blogs. Main ones below:

http://edwatch.blogspot.com (EDUCATION WATCH)

http://antigreen.blogspot.com (GREENIE WATCH)

http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH) Also here

http://australian-politics.blogspot.com (AUSTRALIAN POLITICS)

http://snorphty.blogspot.com (TONGUE-TIED)

https://immigwatch.blogspot.com (IMMIGRATION WATCH) Also here

https://awesternheart.blogspot.com (THE PSYCHOLOGIST)

http://jonjayray.com/blogall.html More blogs

**************************************************